9lione Raises ¥120M Series A

9lione, based in Nerima-ku, Tokyo, operates a DX platform designed to improve pharmaceutical distribution by connecting hospitals with surplus medications to those experiencing shortages. The company has raised 120 million yen in Series A funding, bringing its total funding to 440 million yen.

Investors

The funding round was led by Yokohama Capital. Additional investors participating in the round included Incubate Fund, DG Ventures, Mitsui Sumitomo Insurance Capital, Globe Advisors, Nanobank, and various angel investors.

9lione Use of Funds

The raised capital will be utilized to expand the company's network of logistics and sales bases across Japan. The funds will also support the development of products for medical institutions, including AI-driven inventory visualization and transaction automation, and the strengthening of the company's organizational structure.

About 9lione

Founded in 2018, 9lione provides a digital transformation platform that functions as a licensed pharmaceutical wholesaler. The company manages inventory and traceability to facilitate the redistribution of unused medicines from medical institutions, aiming to reduce waste and alleviate pharmaceutical supply shortages.

Funding Details

Company Website: https://9lione.company

Company: 9lione
Raised: ¥120M
Round: Series A
Funding Date: September 2026
Lead Investor: Yokohama Capital
Additional Investors: Incubate Fund, DG Ventures, Mitsui Sumitomo Insurance Capital, Globe Advisors, Nanobank, angel investors
Company Website: https://9lione.company/
Software Category: HealthTech
Source: https://prtimes.jp/main/html/rd/p/000000008.000042558.html